SMAD3 and prostate carcinoma: SMAD3 reportedly supports the growth of prostate cancer cells under hypoxic conditions [21], further supporting the notion that hypoxic adaptation may represent an important oncogenic function of ONECUT2 and its target genes SMAD3 and EPAS1 in BPDCN.